LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
LAVA Therapeutics N.V. (NASDAQ: LVTX) today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference.
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
Buy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financials
LAVA Therapeutics: A Strong Buy on Robust Financials and Promising Oncology Pipeline Advancements
LAVA Therapeutics GAAP EPS of -$0.24 Beats by $0.18
LAVA Therapeutics Announces Progress and Stability
LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint
Strong Buy Rating for LAVA Therapeutics on Promising Clinical and Financial Outlook
Express News | HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
LAVA Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 103.39% HC Wainwright & Co. → $6 Reiterates Buy → Buy 11/17/2023 103.39% HC Wainwright & Co. →
LAVA Therapeutics Q4 EPS $(0.24) Misses $(0.12) Estimate, Sales $353.00K Miss $6.25M Estimate
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.12) by 100 percent. This is a 57.89 percent increase over losses of $(
Lava Therapeutics: Balance Sheet With Cash of $95.6M Supports Runway Into 2026 >LVTX
Lava Therapeutics: Balance Sheet With Cash of $95.6M Supports Runway Into 2026 >LVTX
Press Release: LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results -- LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2
Lava Therapeutics 4Q Loss/Shr 24c >LVTX
Lava Therapeutics 4Q Loss/Shr 24c >LVTX
Lava Gets $7M From Pfizer as Trial for Cancer Drug Advances
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and
Express News | LAVA Therapeutics Shares Are Trading Higher After the Company Announced a $7 Million Payment Because Pfizer Achieved a Clinical Milestone for PF-08046052
Express News | LAVA Therapeutics Announces Pfizer Has Achieved Clinical Development Milestone For PF-08046052, Triggering $7M Payment To LAVA
LVTX, VIEW and LASE Among Pre-market Losers
Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)
No Data